Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
you are here: HomeNewsOpinion

Divi’s and Gland Pharma’s weak results show B2B model not without risks

Post the weak September quarter results, analysts fear revenue may decline at both the companies in FY23

November 10, 2022 / 11:28 AM IST
Divi’s and Gland Pharma’s weak results show B2B model not without risks

Highlights Divi’s clocked its first quarterly sales drop in years. Gland Pharma saw steady decline in profit margins Performance hit by high costs, delay in projects and slowing COVID drug sales Companies are adding new projects and capacities whose benefits are expected to materialise from the next fiscal year or so  Divi’s Laboratories and Gland Pharma, which thrived on the business to business (B2B) model, have hit a speed breaker. Shares of both these companies slumped after the September quarter results. Divi’s clocked...

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers